Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Rosetta to Develop Liver Toxicity Database for Abbott Labs

NEW YORK, Nov 30 – Rosetta Inpharmatics will develop a database for Abbott Laboratories that will include gene expression profiles for compounds that produce toxic responses in animals and human liver systems, Rosetta announced Thursday.

The companies will jointly create the gene expression profiles of compounds chosen by Abbott using Rosetta’s Flexjet microarray platform and the Rosetta Resolver expression analysis tool.

" This a direct drill into an area we think is very important and that we are very well suited to work on,” said Rosetta CEO Stephen Friend.    The ultimate goal of the collaboration, Friend added, is to develop “models that will allow you to do risk assessment, not only in animals, but in clinical trials.”

Each company has said it would fund its own efforts in the collaboration, but neither disclosed further terms of the agreement.

By comparing the human and animal liver toxicity profiles, the companies hope to distinguish between the human and animal responses, and develop algorithms that researchers can use to predict human toxicity responses to compounds based on animal models.

Rosetta hopes the collaboration will help it build its technology for other collaborations, including technologies that allow researchers to use gene expression profiling to rapidly weed out potentially toxic drug candidates in the drug development process.

The partnership, said Friend, underscores the company’s core strategy of focusing on collaborations rather than just being a tool provider.

Rosetta has recently signed other gene expression profiling collaborations with Monsanto and Gemini Genomics, and has sold its Rosetta Resolver, which Agilent technologies distributes, to a number of pharmaceutical, biotechnology, and academic customers.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.